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OBJECTIVE: The ASP is one of the most frequent infectious
diseases and represents one of the principal causes of outpatient
services demand in Mexico. The purpose of this study was to
estimate the cost-effectiveness between single-dose azithromycin
microspheres formulation vs. other usual antibiotics in the man-
agement of ASP from the Mexican Health Service perspective.
METHODS: A three-month Bayesian decision tree model was
performed to estimate costs and effectiveness. Effectiveness
measure used was the percentage of clinical success rate (signiﬁ-
cant improvement of symptoms in a period not longer than a
four-day treatment). Comparators employed were single-dose
azithromycin oral suspension (60 ml); amoxicillin (1000 mg/day);
penicillin (600,000 U/day); ampicillin (1500 mg/day); clarithro-
mycin (500 mg/day); erythromycin (1000 mg/day) trimetoprim +
sulfametoxazol and azithromycin (500 mg/day per 3 d). Clinical
efﬁcacy was obtained from international published literature.
Resource use data and costs were obtained from a retrospective
review of hospital records (n = 100) in patients treated at the
Social Security Mexican Institute (IMSS) in Mexico City. The
model was calibrated. One-way sensitivity analysis and probabi-
listic sensitivity analyses were performed. MonteCarlo ﬁrst order
sensitivity analysis was done using bootstrapping techniques.
RESULTS: The patients treated with azithromycin oral-
suspension experienced the highest effectiveness (93%; CI95%
90%–97%), followed for azithromycin (3-days) treatment (79%;
CI95% 77%–81%) and erythromycin (67%, CI95% 66%–
68%). On the other hand, amoxicillin and trimetoprim showed
the less effectiveness compared to the baseline therapy (penicillin
[57%; IC95% 56%–58%]). The mean treatment costs for
azithromycin oral-suspension was US$110.9 (CI95% US$109.3–
US$112.1); US$122.3 (CI95% $1329.10–$1365.56) for
azithromycin (3-days) and US$128.1 (CI95% US$127.0–
US$132.2) with erythromycin. The ICER’s were US$-49.8
(CI95% -US$41.7,-US$60.4) for azithromycin oral-suspension,
-US$30.6 (CI95% -US$20.0,-US$40.4) and -US$25.5 (CI95%
-US$21.9,-US$30.36) for erythromycin. Probabilistic sensitivity
analyses showed that the single-dose azithromycin oral-
suspension was the dominant therapy (p < 0.05). CONCLU-
SION:Despite its higher cost, the study demonstrates that azithro-
mycin oral-suspension treatment, due to its higher compliance
rate, is a dominant therapy in the treatment of ASP in Mexico.
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OBJECTIVE: To evaluate the cost effectiveness and cost utility of
sunitinib compared with interferon-alfa (IFN-alfa) for ﬁrst-line
treatment of patients with Metastatic Renal Cell Carcinoma
(mRCC) from Colombia third-party payer perspective.
METHODS: A Markov model was developed and adapted to
Colombian circumstances to evaluate the cost-effectiveness of
sunitinib vs. IFN-alfa. The model projected survival and costs in
6-week cycles based on extrapolation of the trial survival data.
The reference case analysis followed the patients until death or
for up to 1 year, however longer time horizons were considered
in the analysis (two, ﬁve, and ten years). Effectiveness was mea-
sured in terms of progression-free life years (PFLY), life-years
(LY) gained and quality adjusted life-years (QALY) gained.
Resource utilization and unit cost data were collected from: A
series of 15 patients with mRCC treated in Colombia, Colom-
bian expert clinical opinion and the cost of medication was
extracted from a Colombian Cancer reference institution (Liga
Colombiana de lucha contra el cáncer). Costs and beneﬁts were
discounted annually at 5%. All costs were calculated in 2006
Colombian pesos. Univariate sensitivity analyses was conducted.
RESULTS: For the reference case: the cost analysis suggested a
difference in favor of sunitinib of US$5711. The treatment with
sunitinib was associated with incremental gain in: PFLY of 0.23,
overall survival of 0.05 YL and QALY of 0.07. The incremental
cost-effectiveness ratio (ICER) and incremental cost-utility ratio
(ICUR) showed negative values, which indicated that sunitinib is
cost saving versus IFN-alfa. In the longer time horizon analysis
the sunitinib is dominant in the ﬁrst two years; for 5 and 10 years
analysis the ICER and the ICUR are around US$8200 and
US$6400 respectively. CONCLUSION: This analysis indicated
that sunitinib is a cost-effective treatment compared with IFN-
alfa as a ﬁrst-line treatment in mRCC in Colombia.
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OBJECTIVE: To investigate the economic impact of introducing
micafungin (MICA) for the treatment of systemic candida infec-
tions (SCIs) (including invasive candidiasis and candidaemia) in
the UK, a health economic analysis was performed comparing
MICA with liposomal amphotericin B (L-AMB). METHODS:
The model was based on data from a phase III, randomised,
double-blind trial which compared MICA with L-AMB. The
model period entails 14–20 weeks starting from initiation of
treatment and was analysed from a UK hospital perspective.
Hospitalisation and primary medication costs were included in
the current analysis. Unit costs of these resources were taken
from appropriate UK costing sources. As the price for MICA was
not available at the time of analysis, the price per recommended
daily dose (RDD) of MICA (100 mg) was assumed to be equal to
the price per RDD of caspofungin (50 mg). The model endpoint
was deﬁned as the percentage of patients that achieved complete
or partial clinical and mycological response after initial treat-
ment, and were alive after the 12-week follow-up period. The
model was analysed using cohort and second order Monte Carlo
(MC) simulation. RESULTS: The analysis shows that with MICA
52.9% of patients were successfully treated and survived 12
weeks after treatment ends compared to 49.1% for L-AMB.
MICA was also less expensive than L-AMB costing £26,838 and
£29,549 per patient, respectively. Because the costs are lower
and the effectiveness is higher for MICA (cost-effectiveness
[C/E] ratio = £50,755) in comparison with L-AMB (C/E
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